https://doi.org/10.55788/236b8e48
The current phase 2 trial (NCT03672773) evaluated the efficacy of the PARP inhibitor talazoparib in combination with temozolomide in 28 patients with relapsed or refractory ES-SCLC. Dr Jonathan Goldman (David Geffen School of Medicine at UCLA, CA, USA) presented the findings. An objective response rate (ORR) of 29% was needed to meet the primary endpoint.
The ORR was 39.3%, representing 11 patients with partial responses. The median time to response was 1.8 months, and the median duration of response was 4.3 months. In addition, the progression-free survival was 4.3 months and the overall survival was 11.9 months.
Haematologic adverse events (AEs) were commonly observed in this patient population. A total of 53.6%, 32.1%, and 60.7% of the participants experienced grade 3 or 4 anaemia, decreased neutrophil count, or decreased platelet count, respectively. The most frequently observed non-haematologic AEs were fatigue, nausea, diarrhoea, and anorexia, predominantly being grade 1 or 2 events. Dr Goldman mentioned that exploratory results are currently being investigated. āThis is the second study to demonstrate the clinical benefits of a PARP inhibitor in combination with temozolomide in patients with SCLC,ā added Dr Goldman [2]. āTherefore, a phase 3 trial is appropriate to confirm the safety and efficacy of this combination regimen in SCLC.ā
- Goldman J, et al. Phase 2 study analysis of talazoparib plus temozolomide for extensive-stage small cell lung cancer (ES-SCLC). OA12.03, WCLC 2022, Vienna, Austria, 06ā09 August.
- Farago AF, et al. Cancer Discov. 2019 Oct;9(10):1372-1387.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Pembrolizumab plus lenvatinib performs well in MPM Next Article
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC »
« Pembrolizumab plus lenvatinib performs well in MPM Next Article
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC »
Table of Contents: WCLC 2022
Featured articles
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
WCLC 2022 Congress Round-Up
Sugemalimab offers PFS benefits for unresectable NSCLC
First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
NADIM: Risk of progression identified through RNA sequencing
NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?
First DLL3-targeted therapy shows promise in SCLC
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Pembrolizumab plus lenvatinib performs well in MPM
Early detection strategies in younger patients with lung cancer are urgently needed
Intensive co-located smoking cessation programme highly effective during lung screening
Do we underestimate the effect of air pollution on lung cancer incidence?
Interventions needed to address sexual health in lung cancer
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com